Global Hospital Pharmaceuticals (Cardiology, Oncology, Nephrology & Urology, Neurology, Pain and Infection) Market - Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

DUBLIN, December 8, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/bhndxn/hospital) has announced the addition of the "Hospital Pharmaceuticals Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering.

     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

Hospital pharmaceuticals include drugs and medications that are exclusively sold at hospitals, clinics or any other professional healthcare facility other than skilled nursing facilities. Drugs under hospital pharmaceuticals range from paracetamol used to ease pain and minor aches to prescription drugs prescribed for several chronic diseases such as blood pressure, diabetes and cancer. On average public hospitals, through their pharmacies in the United States spend approximately USD 200 million annually on the purchase of various pharmaceuticals products.

In developed economic regions such as the United States and Europe purchase of pharmaceuticals in hospital is majorly driven by government policies that primarily aim to assure that hospitals achieve fair value for money and access to government procurement policies. Market for hospital pharmaceuticals is majorly driven by increasing prevalence of chronic and acute diseases worldwide.

The global hospital pharmaceuticals market is studied from two perspectives: major therapeutic class and indications. Market for hospital pharmaceuticals by indications is further sub-segmented into cardiology, oncology, nephrology and urology, neurology, pain and infection. Each of the aforementioned indication is further studied on the basis of the prominently occurring diseases. For instance market for cardiology is further categorized into stroke, high blood pressure, heart failure and other cardiovascular diseases such as arrhythmia and cardiomyopathy.

Similarly the oncology therapeutic segment is further studied for lung cancer, breast cancer, colorectal cancer, prostate cancer and others which include oesophageal, stomach and liver cancer. Similar protocol is followed for other indications as well. Furthermore the market for hospitals pharmaceuticals market by major therapeutic class include major drug classes prescribed under each of the indications mentioned above. The global hospital pharmaceuticals market was valued at USD 26,580.9 million in 2013 and is estimated to reach USD 10,907.5 million in 2020, declining with a CAGR of (11.5)% from 2014 to 2020.

The oncology segment accounts for the largest market share in 2013 wherein the immunomodulating agent holds the maximum share among other drug class commonly prescribed in hospital settings. Followed by oncology, cardiovascular disease account for the second largest share in which anti-cholinergic agent has the fastest declining growth rate. Decline in anti-cholinergic agent is primarily due to exclusivity loss of several high selling drugs such as VESIcare and Enablex which will lose their patent rights in 2015 and 2018 respectively.

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Executive Summary

Chapter 3 Global Hospital Pharmaceutical Market Overview

Chapter 4 Global Hospital Pharmaceutical Market, by Major Therapeutic Class

Chapter 5 Global Hospital Pharmaceutical Market, by Indication

Chapter 6 Hospital Pharmaceuticals Market, by Geography

Chapter 7 Recommendations

Chapter 8 Company Profiles


Companies Mentioned:

• AstraZeneca plc
• Bayer AG
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer, Inc.
• Sanofi-Aventis

For more information visit http://www.researchandmarkets.com/research/bhndxn/hospital

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets